Convalescent Plasma Therapy for COVID-19: Current Status and Future Directions

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) has triggered a global health crisis probably due to a lack of a reliable cure till date. Several clinical trials are ongoing, but initial results have not been overly promising. Convalescent plasma (CP), which refers to plasma collected from individuals recovered from an illness and developed antibodies against the pathogen, is also being proposed as a therapeutic option for COVID-19 treatment in severe cases to achieve short-term immunity against the virus. Use of CP is not new, and it has been used in various outbreaks over the past century, ranging from the Spanish influenza outbreak in 1918 to the recent Middle East respiratory syndrome (MERS). However, data available on its use in COVID-19 patients is limited. Use of CP so far is restricted to a “rescue therapy” and needs further trials to assess its possible use in other situations (prevention, postexposure prophylaxis) and patient populations (considering age and comorbid illnesses). In this review, we will try to summarize the current status of use of CP for COVID-19 and ongoing trials in India and elsewhere and will discuss the possible avenues for its use in future.

A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.

“…Administration of non-matched ABO blood can result in significant consequences, such as anaphylaxis. With the use of the current screening tools, the risk of blood pathogen transmission due to transfusion is extremely low [220] . However, in one patient receiving convalescent plasma, a study described a very tiny side effect of an evanescent face red spot, but there were no other negative side effects [221] .…”